Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Amortization of Deferred Charges (2016 - 2017)

BioCorRx's Amortization of Deferred Charges history spans 3 years, with the latest figure at $9.4 million for Q1 2017.

  • For Q1 2017, Amortization of Deferred Charges rose 43004.89% year-over-year to $9.4 million; the TTM value through Dec 2017 reached $9.4 million, up 13901.32%, while the annual FY2017 figure was $9.4 million, 13901.32% up from the prior year.
  • Amortization of Deferred Charges for Q1 2017 was $9.4 million at BioCorRx, up from $45152.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $9.4 million in Q1 2017 and bottomed at $14966.0 in Q2 2015.
  • The 3-year median for Amortization of Deferred Charges is $45152.0 (2016), against an average of $1.4 million.
  • The largest annual shift saw Amortization of Deferred Charges crashed 69.56% in 2016 before it surged 43004.89% in 2017.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $35488.0 in 2015, then increased by 27.23% to $45152.0 in 2016, then skyrocketed by 20637.16% to $9.4 million in 2017.
  • Per Business Quant, the three most recent readings for BICX's Amortization of Deferred Charges are $9.4 million (Q1 2017), $45152.0 (Q4 2016), and $21722.0 (Q1 2016).